Anteris Technologies Global Corp. (ASX:AVR)

Market Cap	1.26B +419.3%
Revenue (ttm)	2.70M -25.8%
Net Income	-138.86M
EPS	-2.85
Shares Out	97.34M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	39,149
Average Volume	32,878
Open	12.70
Previous Close	12.54
Day's Range	12.61 - 13.01
52-Week Range	4.69 - 13.00
Beta	0.59
RSI	80.88
Earnings Date	Aug 21, 2026

About ASX:AVR

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tiss...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1999
• Employees: 174
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: AVR

Financial Performance

In 2025, ASX:AVR's revenue was $1.91 million, a decrease of -29.23% compared to the previous year's $2.70 million. Losses were -$94.14 million, 23.4% more than in 2024.

Financial numbers in USD